Related Experiment Video
Updated: Jun 6, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
Post-surgery severe hypocalcemia in primary hyperparathyroidism preoperatively treated with zoledronic acid
Salvatore Maria Corsello1, Rosa Maria Paragliola, Pietro Locantore
1Department of Endocrinology, Catholic University School of Medicine, Largo A. Gemelli, Rome, Italy. corsello.sm@mclink.it
Zoledronic acid, used off-label for hyperparathyroidism, may worsen postoperative hypocalcemia. This case highlights potential risks of bisphosphonate use before parathyroid surgery, suggesting enhanced monitoring is needed.
Area of Science:
- Endocrinology
- Pharmacology
- Nephrology
Background:
- Zoledronic acid is an FDA-approved bisphosphonate for hypercalcemia of malignancy.
- Its use for hypercalcemia in primary hyperparathyroidism is off-label, lacking established safety and efficacy data.
- Primary hyperparathyroidism can lead to severe hypercalcemia, requiring management before surgical intervention.
Observation:
- A 64-year-old woman with primary hyperparathyroidism received zoledronic acid for severe hypercalcemia.
- Preoperative treatment with zoledronic acid led to profound hypocalcemia, resistant to standard treatments post-parathyroidectomy.
- The patient experienced prolonged hypocalcemia, resolving only after three months.
Findings:
- Preoperative bisphosphonate therapy, specifically zoledronic acid, may exacerbate hungry bone syndrome post-parathyroid surgery.
- This exacerbation can lead to severe, treatment-resistant postoperative hypocalcemia.
- The patient required extended calcium supplementation to normalize serum calcium levels.
Implications:
- Clinicians should exercise caution when using zoledronic acid off-label for hyperparathyroidism, especially preoperatively.
- Enhanced monitoring for and management of hypocalcemia may be necessary in patients treated with bisphosphonates before parathyroidectomy.
- Further clinical trials are warranted to establish the safety and efficacy of bisphosphonates in managing hyperparathyroidism-related hypercalcemia.
Related Concept Videos
Skeleton and Calcium Homeostasis
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Peripheral Artery Disease V: Postoperative Nursing Management
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling